As a leading expert in preclinical drug discovery, Creative Biolabs provides a full range of antibacterial drug discovery services for global customers. Based on our extensive experience and well-established platforms, we are able to discover novel antibiotics for the treatment of severe bacterial pathogen infections. Our scientists are happy to promote the development of worldwide clients’ programs, which including but not limited to discover new antibiotics against Pseudomonas Aeruginosa (P. aeruginosa).
P. aeruginosa is an aerobic gram-negative bacterium that is typified by motile, non-spore forming rods that are oxidase-positive and lactose nonfermenters. As a member of the genus Pseudomonas, P. aeruginosa is ubiquitous. It is an opportunistic human pathogen capable of causing a wide array of life-threatening acute and chronic infections, particularly in patients with compromised immune defense. Recently, P. aeruginosa infection presents a serious therapeutic challenge for the treatment of both community-acquired and nosocomial infections, and the selection of the appropriate antibiotic to initiate therapy is essential to optimizing the clinical outcome. Unfortunately, the selection of the most appropriate antibiotic is complicated by the ability of P. aeruginosa to develop resistance to multiple classes of antibacterial agents, especially during treating an infection.
Indeed, the emergence of antibiotic-resistant bacteria is a global health issue. Studies have shown that P. aeruginosa displays resistance to a variety of antibiotics, including aminoglycosides, quinolones, and β-lactams. The resistance capacity of P. aeruginosa can be developed through various molecular mechanisms that are often simultaneously present in clinical isolates. Although each resistance mechanism is related to a specific class of antibiotics, multiple mechanisms mediate variable resistance to each class of antibiotics. Generally, loss or reduced copy numbers of OprD and overproduction of active efflux pumps, AmpC β-lactamase, and extended-spectrum β-lactamases have been mainly reported as main contributors to multi-drug resistance phenotypes of P. aeruginosa. These mechanisms are often present in combination, causing a broad range of antibiotics to be rendered ineffective against a given P. aeruginosa isolate.
Fig.1 A schematic illustration showing the complexity of the interplay of virulence factors and antimicrobial resistance mechanisms of P. aeruginosa. (El Zowalaty, 2015)
Conventional antibiotic therapies against P. aeruginosa infections have become increasingly ineffective due to the rise of multidrug-resistant strains. Thus, the development of novel antibiotics or alternative therapeutic strategies to treat P. aeruginosa infections is highly desirable and has gained more attention in the past decade. One potential strategy is to target the regulation of bacterial resistance mechanisms as a pathway to enhance the potency of available drugs and, perhaps, restore the efficacy of available drugs. To date, multiple novel therapeutic strategies have been developed such as inhibition of quorum sensing and bacterial lectins, as well as the use of iron chelation, phage therapy, vaccine strategy, the use of nanoparticles, antimicrobial peptides and electrochemical scaffolds. These therapeutic strategies can act either alone or in combination with conventional therapies to combat P. aeruginosa infections.
With years of experience in preclinical drug discovery, Creative Biolabs has successfully established an advanced technology platform that enables us to help global customers discover new antibiotics in both medicinal chemistry and target-based drug discovery way. Our professional scientists will help you select the most appropriate target using multiple screening strategies. Moreover, we can also help clients modify the natural antibiotic scaffolds to produce new antibiotics with higher activity than the original.
Creative Biolabs has extensive experience in the area of antibiotic development. Our scientists are confident in offering the best services through our top platforms. If you are interested in the services we offer, please feel free to contact us for more details.
Reference
For Research Use Only.
